User profiles for Jeffrey M. Drazen

Jeffrey M. Drazen

Professor, Harvard Medical School
Verified email at nejm.org
Cited by 74582

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

JM Drazen, CN Yandava, L Dubé, N Szczerback… - Nature …, 1999 - nature.com
Clinically similar asthma patients may develop airway obstruction by different mechanisms 1,
2. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway 3, …

The biology of nitrogen oxides in the airways.

B Gaston, JM Drazen, J Loscalzo… - American journal of …, 1994 - atsjournals.org
Nitrogen oxides (NOx), regarded in the past primarily as toxic air pollutants, have recently
been shown to be bioactive species formed endogenously in the human lung. The relationship …

Mechanotransduction through growth-factor shedding into the extracellular space

…, PTC So, DA Lauffenburger, RD Kamm, JM Drazen - Nature, 2004 - nature.com
Physical forces elicit biochemical signalling in a diverse array of cells, tissues and organisms
1 , 2 , 3 , helping to govern fundamental biological processes. Several hypotheses have …

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma

JM Drazen, E Israel, HA Boushey… - … England Journal of …, 1996 - Mass Medical Soc
Background Inhaled β-agonists are the most commonly used treatment for asthma, but data
suggest that regularly scheduled use of these agents may have a deleterious effect on the …

Global strategy for asthma management and prevention: GINA executive summary

…, J Bousquet, JM Drazen, M FitzGerald… - European …, 2008 - Eur Respiratory Soc
Asthma is a serious health problem throughout the world. During the past two decades, many
scientific advances have improved our understanding of asthma and ability to manage and …

Treatment of asthma with drugs modifying the leukotriene pathway

JM Drazen, E Israel, PM O'Byrne - New England Journal of …, 1999 - Mass Medical Soc
In 1979 and 1980, the chemical structures of the material previously known as slow-reacting
substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,…

Clinical trial registration: a statement from the International Committee of Medical Journal Editors

C De Angelis, JM Drazen, FA Frizelle, C Haug, J Hoey… - The Lancet, 2004 - thelancet.com
In today’s Lancet, the INTERHEART study investigators report a well-coordinated study of
risk factors for myocardial infarction in multiple populations. They present hazard ratios and …

Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes

…, R Buhl, AA Cruz, L Duijts, JM Drazen… - American journal of …, 2022 - atsjournals.org
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …

Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro.

JM Drazen, KF Austen, RA Lewis… - Proceedings of the …, 1980 - National Acad Sciences
The pharmacologic activities of leukotrienes C-1 and D(LTC-1 and LTD), constituents of slow
reacting substance of anaphylaxis (SRS-A), were evaluated in vitro on airway contractile …

Artificial intelligence and machine learning in clinical medicine, 2023

CJ Haug, JM Drazen - New England Journal of Medicine, 2023 - Mass Medical Soc
AI and Machine Learning in Clinical Medicine, 2023 This first article in a series describes the
history of artificial intelligence in medicine; the use of AI in image analysis, identification of …